Resveratrol inhibits the intracellular calcium increase and angiotensin/endothelin system activation induced by soluble uric acid in mesangial cells

Brazilian Journal of Medical and Biological Research

Volumn 48, Issue 1, 2015, Pages 51-56

  Albertoni, G ^a   Schor, N ^a  

^a FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Angiotensin; Endothelin; Intracellular calcium; Mesangial cells; Resveratrol; Uric acid

Indexed keywords

ANGIOTENSIN; ENDOTHELIN RECEPTOR; RESVERATROL; URIC ACID;

ARTICLE; CALCIUM CELL LEVEL; CHRONIC KIDNEY DISEASE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; GENE EXPRESSION; HUMAN; HUMAN CELL; KIDNEY FUNCTION; MESANGIUM CELL; PROTEIN EXPRESSION; PROTEIN SYNTHESIS; REAL TIME POLYMERASE CHAIN REACTION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM;

VITACEAE;

EID: 84916920252     PISSN: None     EISSN: 1414431X     Source Type: Journal    
DOI: 10.1590/1414-431X20144032     Document Type: Article

References (38)

1. Scott E, Steward WP, Gescher AJ, Brown K. Resveratrol in human cancer chemoprevention - choosing the ‘right’ dose. Mol Nutr Food Res 2012; 56: 7-13, doi: 10.1002/mnfr.201100400.
2. Roupe KA, Remsberg CM, Yanez JA, Davies NM. Pharmacometrics of stilbenes: seguing towards the clinic. Curr Clin Pharmacol 2006; 1: 81-101, doi: 10.2174/157488406775268246.
3. Smoliga JM, Baur JA, Hausenblas HA. Resveratrol and health- a comprehensive review of human clinical trials. Mol Nutr Food Res 2011; 55: 1129-1141, doi: 10.1002/mnfr.201100143.
4. Delmas D, Aires V, Limagne E, Dutartre P, Mazue F, Ghiringhelli F, et al. Transport, stability, and biological activity of resveratrol. Ann N Y Acad Sci 2011; 1215: 48-59, doi: 10.1111/j.1749-6632.2010.05871.x.
5. Timmers S, Konings E, Bilet L, Houtkooper RH, van de Weijer T, Goossens GH, et al. Calorie restriction-like effects of 30 days of resveratrol supplementation on energy metabolism and metabolic profile in obese humans. Cell Metab 2011; 14: 612-622, doi: 10.1016/j.cmet.2011.10.002.
6. Brasnyo P, Molnar GA, Mohas M, Marko L, Laczy B, Cseh J, et al. Resveratrol improves insulin sensitivity, reduces oxidative stress and activates the Akt pathway in type 2 diabetic patients. Br J Nutr 2011; 106: 383-389, doi: 10.1017/S0007114511000316.
7. Magyar K, Halmosi R, Palfi A, Feher G, Czopf L, Fulop A, et al. Cardioprotection by resveratrol: A human clinical trial in patients with stable coronary artery disease. Clin Hemorheol Microcirc 2012; 50: 179-187.
8. Kondratyuk TP, Park EJ, Marler LE, Ahn S, Yuan Y, Choi Y, et al. Resveratrol derivatives as promising chemopreventive agents with improved potency and selectivity. Mol Nutr Food Res 2011; 55: 1249-1265, doi: 10.1002/mnfr.201100122.
9. Matsuoka A, Kodama Y, Fukuhara K, Honda S, Hayashi M, Sai K, et al. A pilot study of evaluation of the antioxidative activity of resveratrol and its analogue in a 6-month feeding test in young adult mice. Food Chem Toxicol 2008; 46: 1125-1130, doi: 10.1016/j.fct.2007.11.008.
10. Kim MY, Lim JH, Youn HH, Hong YA, Yang KS, Park HS, et al. Resveratrol prevents renal lipotoxicity and inhibits mesangial cell glucotoxicity in a manner dependent on the AMPK-SIRT1-PGC1alpha axis in db/db mice. Diabetologia 2013; 56: 204-217, doi: 10.1007/s00125-012-2747-2.
11. Shi YW, Wang CP, Liu L, Liu YL, Wang X, Hong Y, et al. Antihyperuricemic and nephroprotective effects of resveratrol and its analogues in hyperuricemic mice. Mol Nutr Food Res 2012; 56: 1433-1444, doi: 10.1002/mnfr.201100828.
12. Khan SR. Hyperoxaluria-induced oxidative stress and antioxidants for renal protection. Urol Res 2005; 33: 349-357, doi: 10.1007/s00240-005-0492-4.
13. Hong SH, Lee HJ, Sohn EJ, Ko HS, Shim BS, Ahn KS, et al. Anti-nephrolithic potential of resveratrol via inhibition of ROS, MCP-1, hyaluronan and osteopontin in vitro and in vivo. Pharmacol Rep 2013; 65: 970-979, doi: 10.1016/S1734-1140(13)71078-8.
14. Zhang L, Pang S, Deng B, Qian L, Chen J, Zou J, et al. High glucose induces renal mesangial cell proliferation and fibronectin expression through JNK/NF-kappaB/NADPH oxidase/ROS pathway, which is inhibited by resveratrol. Int J Biochem Cell Biol 2012; 44: 629-638, doi: 10.1016/j.biocel.2012.01.001.
15. Ha H, Hwang IA, Park JH, Lee HB. Role of reactive oxygen species in the pathogenesis of diabetic nephropathy. Diabetes Res Clin Pract 2008; 82 (Suppl 1): S42-S45, doi: 10.1016/j.diabres.2008.09.017.
16. Forbes JM, Coughlan MT, Cooper ME. Oxidative stress as a major culprit in kidney disease in diabetes. Diabetes 2008; 57: 1446-1454, doi: 10.2337/db08-0057.
17. Kashihara N, Haruna Y, Kondeti VK, Kanwar YS. Oxidative stress in diabetic nephropathy. Curr Med Chem 2010; 17: 4256-4269, doi: 10.2174/092986710793348581.
18. Shi YW, Wang CP, Liu L, Liu YL, Wang X, Hong Y, et al. Antihyperuricemic and nephroprotective effects of resveratrol and its analogues in hyperuricemic mice. Mol Nutr Food Res 2012; 56: 1433-1444, doi: 10.1002/mnfr.201100828.
19. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods 2001; 25: 402-408, doi: 10.1006/meth.2001.1262.
20. Adebiyi A. RGS2 regulates urotensin II-induced intracellular Ca2+ elevation and contraction in glomerular mesangial cells. J Cell Physiol 2014; 229: 502-511, doi: 10.1002/jcp.24470.
21. Chuang TY, Au LC, Wang LC, Ho LT, Yang DM, Juan CC. Potential effect of resistin on the ET-1-increased reactions of blood pressure in rats and Ca2+ signaling in vascular smooth muscle cells. J Cell Physiol 2012; 227: 1610-8, doi: 10.1002/jcp.22878.
22. Sorokin A. Endothelin signaling and actions in the renal mesangium. Contrib Nephrol 2011; 172: 50-62, doi: 10.1159/000328680.
23. Woodward OM, Kottgen A, Coresh J, Boerwinkle E, Guggino WB, Kottgen M. Identification of a urate transporter, ABCG2, with a common functional polymorphism causing gout. Proc Natl Acad Sci U S A 2009; 106: 10338-10342, doi: 10.1073/pnas.0901249106.
24. McElnea EM, Quill B, Docherty NG, Irnaten M, Siah WF, Clark AF, et al. Oxidative stress, mitochondrial dysfunction and calcium overload in human lamina cribrosa cells from glaucoma donors. Mol Vis 2011; 17: 1182-1191.
25. Pasalic D, Marinkovic N, Feher-Turkovic L. Uric acid as one of the important factors in multifactorial disorders - facts and controversies. Biochem Med 2012; 22: 63-75, doi: 10.11613/BM.2012.007.
26. Albertoni G, Maquigussa E, Pessoa E, Barreto JA, Borges F, Schor N. Soluble uric acid increases intracellular calcium through an angiotensin II-dependent mechanism in immortalized human mesangial cells. Exp Biol Med 2010; 235: 825-832, doi: 10.1258/ebm.2010.010007.
27. Corry DB, Eslami P, Yamamoto K, Nyby MD, Makino H, Tuck ML. Uric acid stimulates vascular smooth muscle cell proliferation and oxidative stress via the vascular reninangiotensin system. J Hypertens 2008; 26: 269-275, doi: 10.1097/HJH.0b013e3282f240bf.
28. Yu MA, Sanchez-Lozada LG, Johnson RJ, Kang DH. Oxidative stress with an activation of the renin-angiotensin system in human vascular endothelial cells as a novel mechanism of uric acid-induced endothelial dysfunction. J Hypertens 2010; 28: 1234-1242.
29. Baldree LA, Stapleton FB. Uric acid metabolism in children. Pediatr Clin North Am 1990; 37: 391-418.
30. Aida Y, Shibata Y, Osaka D, Abe S, Inoue S, Fukuzaki K, et al. The relationship between serum uric acid and spirometric values in participants in a health check: the Takahata study. Int J Med Sci 2011; 8: 470-478, doi: 10.7150/ijms.8.470.
31. Obermayr RP, Temml C, Knechtelsdorfer M, Gutjahr G, Kletzmayr J, Heiss S, et al. Predictors of new-onset decline in kidney function in a general middle-european population. Nephrol Dial Transplant 2008; 23: 1265-1273, doi: 10.1093/ndt/gfm790.
32. Zhang JX, Zhang YP, Wu QN, Chen B. Uric acid induces oxidative stress via an activation of the renin-angiotensin system in 3T3-L1 adipocytes. Endocrine 2014.
33. Doughan AK, Harrison DG, Dikalov SI. Molecular mechanisms of angiotensin II-mediated mitochondrial dysfunction: linking mitochondrial oxidative damage and vascular endothelial dysfunction. Circ Res 2008; 102: 488-496, doi: 10.1161/CIRCRESAHA.107.162800.
34. Wassmann S, Stumpf M, Strehlow K, Schmid A, Schieffer B, Bohm M, et al. Interleukin-6 induces oxidative stress and endothelial dysfunction by overexpression of the angiotensin II type 1 receptor. Circ Res 2004; 94: 534-541, doi: 10.1161/01.RES.0000115557.25127.8D.
35. Victor VM, Apostolova N, Herance R, Hernandez-Mijares A, Rocha M. Oxidative stress and mitochondrial dysfunction in atherosclerosis: mitochondria-targeted antioxidants as potential therapy. Curr Med Chem 2009; 16: 4654-4667, doi: 10.2174/092986709789878265.
36. Opie LH, Lecour S. The red wine hypothesis: from concepts to protective signalling molecules. Eur Heart J 2007; 28: 1683-1693, doi: 10.1093/eurheartj/ehm149.
37. Frankel EN, Kanner J, German JB, Parks E, Kinsella JE. Inhibition of oxidation of human low-density lipoprotein by phenolic substances in red wine. Lancet 1993; 341: 54-457, doi: 10.1016/0140-6736(93)90206-V.
38. Chao HH, Juan SH, Liu JC, Yang HY, Yang E, Cheng TH, et al. Resveratrol inhibits angiotensin II-induced endothelin-1 gene expression and subsequent proliferation in rat aortic smooth muscle cells. Eur J Pharmacol 2005; 515: 1-9, doi: 10.1016/j.ejphar.2005.03.035.